Aglaia Therapeutics becomes Ribonexus, signs exclusive license agreement with Pierre Fabre on small molecules targeting eIF4A, an innovative target in oncology
Ribonexus (previously Aglaia Therapeutics), a biotechnology startup developing promising new therapies that can overcome resistance to current targeted therapies in cancer patients, and French pharmaceutical group Pierre Fabre today announce the signing of an exclusive license agreement on a series Mehr